Cachexia in chronic heart failure: Endocrine determinants and treatment perspectives

Endocrine

Volumn 43, Issue 2, 2013, Pages 253-265

  Mangner, Norman ^a   Matsuo, Yae ^a,b,c   Schuler, Gerhard ^a   Adams, Volker ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b NATIONAL HOSPITAL ORGANIZATION TAKASAKI GENERAL MEDICAL CENTER   (Japan)

^c GUNMA UNIVERSITY   (Japan)

Author keywords

Cachexia; Endocrine factors; Exercise training; Heart failure; Skeletal muscle

Indexed keywords

ADIPONECTIN; ADRENALIN; ANDROGEN; ANGIOTENSIN II; GAMMA INTERFERON; GHRELIN; GROWTH HORMONE; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; MYOSTATIN; NORADRENALIN; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

BINDING AFFINITY; BINDING SITE; CACHEXIA; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; EXERCISE; HEART FAILURE; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 84879550962     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9767-z     Document Type: Review

References (186)

1. W.J. Evans, J.E. Morley, J. Argiles, C. Bales, V. Baracos, D. Guttridge, A. Jatoi, K. Kalantar-Zadeh, H. Lochs, G. Mantovani, D. Marks, W.E. Mitch, M. Muscaritoli, A. Najand, P. Ponikowski, F. Rossi Fanelli, M. Schambelan, A. Schols, M. Schuster, D. Thomas, R. Wolfe, S.D. Anker, Cachexia: a new definition. Clin. Nutr. 27, 793-799 (2008)
2. W.J. Evans, What is sarcopenia? J. Gerontol. A Biol. Sci. Med. Sci. 50, 5-8 (1995)
3. S.D. Anker, P. Ponikowski, S. Varney, T.P. Chua, A.L. Clark, K.M. Webb-Peploe, D. Harrington, W.J. Kox, P. Poole-Wilson, A.J.S. Coats, Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349, 1050-1053 (1997)
4. W.E. Mitch, A.L. Goldberg, Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N. Engl. J. Med. 335, 1897-1905 (1996)
5. P.O. Hasselgren, J.E. Fischer, Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann. Surg. 233, 9-17 (2001)
6. H.L. Eley, S.T. Russell, M.J. Tisdale, Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem. J. 407, 113-120 (2007)
7. K. Lenk, G. Schuler, V. Adams, Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J. Cachexia Sarcopenia Muscle 1, 9-21 (2010)
8. M. Brink, A. Anwar, P. Delafontaine, Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia. Int. J. Cardiol. 85, 111-121 (2002)
9. 2+-dependent proteolysis in muscle wasting. Int. J. Biochem. Cell Biol. 37, 2134-2146 (2005)
10. S.H. Lecker, R.T. Jagoe, A. Gilbert, M. Gomes, V.E. Baracos, J. Bailey, S.R. Price, W.E. Mitch, A.L. Goldberg, Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18, 39-51 (2004)
11. M.T. Pepato, R.H. Migliorini, A.L. Goldberg, I.C. Kettelhut, Role of different proteolytic pathways in degradation of muscle protein from streptozotocin-diabetic rats. Am. J. Physiol. Endocrinol. Metab. 271, E340-E347 (1996)
12. T.N. Sato, Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376, 70-74 (1995)
13. A. Yndestad, J.K. Damas, E. Oie, T. Ueland, L. Gullestad, P. Aukrust, Role of inflammation in the progression of heart failure. Curr. Cardiol. Rep. 9, 236-241 (2007)
14. D. Hasper, M. Hummel, F.X. Kleber, I. Reindl, H.D. Volk, Systemic inflammation in patients with heart failure. Eur. Heart J. 19, 761-765 (1998)
15. S. Anker, A.L. Clark, M. Kemp, C. Salsbury, M.M. Teixeira, P.G. Hellewell, A.J.S. Coats, Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J. Am. Coll. Cardiol. 30, 997-1001 (1997)
16. M. Rauchhaus, V. Koloczek, H. Volk, M. Kemp, J. Niebauer, D.P. Francis, A.J. Coats, S.D. Anker, Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int. J. Cardiol. 76, 125-133 (2000)
17. B. Levine, J. Kalman, L. Mayer, H.M. Fillit, M.P. Packer, Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323, 236-241 (1990)
18. M. Rauchhaus, W. Doehner, D.P. Francis, C. Davos, M. Kemp, C. Liebenthal, J. Niebauer, J. Hooper, H.D. Volk, A.J.S. Coats, S.D. Anker, Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102, 3060-3067 (2000)
19. A. Deswal, N.J. Petersen, A.M. Feldman, J.B. Young, B.G. White, D.L. Mann, Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103, 2055-2059 (2001)
20. C. Cappuzzello, L. Di Vito, R. Melchionna, G. Melillo, L. Silvestri, E. Cesareo, F. Crea, G. Liuzzo, A. Facchiano, M. Capogrossi, M. Napolitano, Increase of plasma IL-9 and decrease of plasma IL-5, IL-7, and IFN-gamma in patients with chronic heart failure. J. Transl. Med. 9, 28-34 (2011)
21. M. Niethammer, M. Sieber, S. von Haehling, S.D. Anker, T. Munzel, G. Horstick, S. Genth-Zotz, Inflammatory pathways in patients with heart failure and preserved ejection fraction. Int. J. Cardiol. 129, 111-117 (2008)
22. C. Garcia-Martinez, F.J. Lopez-Soriano, J.M. Argiles, Acute treatment with tumor necrosis factor-alpha induces changes in protein metabolism in rat skeletal muscle. Mol. Cell. Biochem. 125, 11-18 (1993)
23. Y.P. Li, R.J. Schwartz, I.D. Waddell, B.R. Holloway, M.B. Reid, Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-B activation in response to tumor necrosis factor alpha. FASEB J. 12, 871-880 (1998)
24. B. Barton, IL-6-like cytokines and cancer cachexia. Immunol. Res. 23, 41-58 (2001)
25. S. Acharyya, K.J. Ladner, L.L. Nelsen, J. Damrauer, P.J. Reiser, S. Swoap, D.C. Guttridge, Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 114, 370-378 (2004)
26. J. Cheng, K. Turksen, Q.C. Yu, H. Schreiber, M. Teng, E. Fuchs, Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF alpha transgenic mice. Genes Dev. 6, 1444-1456 (1992)
27. V. Adams, N. Mangner, A. Gasch, C. Krohne, S. Gielen, S. Hirner, H.J. Thierse, C.C. Witt, A. Linke, G. Schuler, S. Labeit, Induction of MuRF1 is essential for TNF-[alpha]-induced loss of muscle function in mice. J. Mol. Biol. 384, 48-59 (2008)
28. A. Oliff, D. Defeo-Jones, M. Boyer, D. Martinez, D. Kiefer, G. Vuocolo, A. Wolfe, S.H. Socher, Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50, 555-563 (1987)
29. K.A. Baltgalvis, F.G. Berger, M.M. Pena, J.M. Davis, S.J. Muga, J.A. Carson, Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R393-R401 (2008)
30. J. Batista, R.V.T. Santos, L.M. Cunha, K. Mattos, E.M. Oliveira, M.C.L. Seelaender, L.F.B.P. Costa Rosa, Changes in the pro-inflammatory cytokine production and peritoneal macrophage function in rats with chronic heart failure. Cytokine 34, 284-290 (2006)
31. M.A. Panaro, N. Gagliardi, C. Saponaro, R. Calvello, V. Mitolo, A. Cianciulli, Toll-like receptor 4 mediates LPS-induced release of nitric oxide and tumor necrosis factor-alpha by embryonal cardiomyocytes: biological significance and clinical implications in human pathology. Curr. Pharm. Des. 16, 766-774 (2010)
32. X.Q. Li, W. Cao, T. Li, A.G. Zeng, L.L. Hao, X.N. Zhang, Q.B. Mei, Amlodipine inhibits TNF-α production and attenuates cardiac dysfunction induced by lipopolysaccharide involving PI3K/Akt pathway. Int. Immunopharmacol. 9, 1032-1041 (2009)
33. B.M. Meador, C.P. Krzyszton, R.W. Johnson, K.A. Huey, Effects of IL-10 and age on IL-6, IL-1beta, and TNF-α responses in mouse skeletal and cardiac muscle to an acute inflammatory insult. J. Appl. Physiol. 104, 991-997 (2008)
34. C.H. Lang, C. Silvis, N. Deshpande, G. Nystrom, R.A. Frost, Endotoxin stimulates in vivo expression of inflammatory cytokines tumor necrosis factor alpha, interleukin-1-beta, -6, and high-mobility-group protein-1 in skeletal muscle. Shock 19, 538-546 (2003)
35. A. Sandek, M. Rauchhaus, S.D. Anker, S. von Haehling, The emerging role of the gut in chronic heart failure. Curr. Opin. Clin. Nutr. Metab. Care 11, 632-639 (2008)
36. A. Sandek, J. Bauditz, A. Swidsinski, S. Buhner, J. Weber-Eibel, S. von Haehling, W. Schroedl, T. Karhausen, W. Doehner, M. Rauchhaus, P. Poole-Wilson, H.D. Volk, H. Lochs, S.D. Anker, Altered intestinal function in patients with chronic heart failure. J. Am. Coll. Cardiol. 50, 1561-1569 (2007)
37. S. Genth-Zotz, S. von Haehling, A.P. Bolger, P.R. Kalra, R. Wensel, A.J.S. Coats, S.D. Anker, Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am. J. Cardiol. 90, 1226-1230 (2002)
38. Y.P. Li, M.B. Reid, NF-kB mediates the protein loss induced by TNF-α in differentiated skeletal muscle. Am. J. Physiol. 279, R1165-R1170 (2000)
39. S.C. Kandarian, R.W. Jackman, Intracellular signaling during skeletal muscle atrophy. Muscle Nerve 33, 155-165 (2006)
40. D. Cai, J.D. Frantz, N.E. Tawa, P.A. Melendez, B.C. Oh, H.G.W. Lidov, P.O. Hasselgren, W.R. Frontera, J. Lee, D.J. Glass, S.E. Shoelson, IKK[beta]/NF-[kappa]B activation causes severe muscle wasting in mice. Cell 119, 285-298 (2004)
41. M. Buck, M. Chojkier, Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J. 15, 1753-1765 (1996)
42. J.M. Sacheck, A. Ohtsuka, S.C. McLary, A.L. Goldberg, IGF-1 stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Physiol. Endocrinol. Metab. 287, E591-E601 (2004)
43. Y.P. Li, Y. Chen, J. John, J. Moylan, B. Jin, D.L. Mann, M.B. Reid, TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. 19, 362-370 (2005)
44. E. Latres, A.R. Amini, A.A. Amini, J. Griffiths, F.J. Martin, Y. Wei, H.C. Lin, G.D. Yancopoulos, D.J. Glass, Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J. Biol. Chem. 280, 2737-2744 (2005)
45. V. Adams, A. Linke, U. Wisloff, C. Doring, S. Erbs, N. Krankel, C.C. Witt, S. Labeit, U. Muller-Werdan, G. Schuler, R. Hambrecht, Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility. Cardiovasc. Res. 73, 120-129 (2007)
46. V. Adams, B. Nehrhoff, U. Späte, A. Linke, P.C. Schulze, A. Baur, S. Gielen, R. Hambrecht, G. Schuler, Induction of iNOS-expression in skeletal muscle by IL-1ß and NFκB activation: an in vitro and in vivo study. Cardiovasc. Res. 54, 95-104 (2002)
47. S. Di Marco, R. Mazroui, P. Dallaire, S. Chittur, S.A. Tenenbaum, D. Radzioch, A. Marette, I.E. Gallouzi, NF-kappa B-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release. Mol. Cell. Biol. 25, 6533-6545 (2005)
48. B.M. Matata, M. Galinanes, Peroxynitrite is an essential component of cytokines production mechanism in human monocytes through modulation of nuclear factor- B DNA binding activity. J. Biol. Chem. 277, 2330-2335 (2002)
49. S. Gielen, V. Adams, A. Linke, S. Erbs, S. MÂbius-Winkler, A. Schubert, G. Schuler, R. Hambrecht, Exercise training in chronic heart failure: correlation between reduced local inflammation and improved oxidative capacity in the skeletal muscle. Eur. J. Cardiovasc. Prev. Rehabil. 12, 393-400 (2005)
50. H. Steller, Mechanisms and genes of cellular suicide. Science 267, 1445-1449 (1995)
51. L. Dalla-Libera, R. Sabbadini, C. Renken, B. Ravara, M. Sandri, R. Betto, A. Angelini, G. Vescovo, Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-α and sphingosine. J. Mol. Cell. Cardiol. 33, 1871-1878 (2001)
52. G. Vescovo, L. Dalla-Libera, Skeletal muscle apoptosis in experimental heart failure: The only link between inflammation and skeletal muscle wastage? Curr. Opin. Clin. Nutr. Metab. Care 9, 416-422 (2006)
53. V. Adams, H. Jiang, J. Yu, S. Möbius-Winkler, E. Fiehn, A. Linke, C. Weigl, G. Schuler, R. Hambrecht, Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J. Am. Coll. Cardiol. 33, 959-965 (1999)
54. G. Chen, D.V. Goeddel, TNF-R1 signaling: a beautiful pathway. Science 296, 1634-1635 (2002)
55. V.M. Conraads, V.Y. Hoymans, T. Vermeulen, P. Beckers, N. Possemiers, M. De Maeseneer, C. Vrints, W. Martinet, Exercise capacity in chronic heart failure patients is related to active gene transcription in skeletal muscle and not apoptosis. Eur. J. Cardiovasc. Prev. Rehabil. 16, 325-332 (2009)
56. S. von Haehling, S.D. Anker, Future prospects of anticytokine therapy in chronic heart failure. Expert Opin. Investig. Drugs 14, 163-176 (2005)
57. D.L. Mann, J.J.V. McMurray, M. Packer, K. Swedberg, J.S. Borer, W.S. Colucci, J. Djian, H. Drexler, A. Feldman, L. Kober, H. Krum, P. Liu, M. Nieminen, L. Tavazzi, D.J. van Veldhuisen, A. Waldenstrom, M. Warren, A. Westheim, F. Zannad, T. Fleming, Targeted anticytokine therapy in patients with chronic heart failure. Circulation 109, 1594-1602 (2004)
58. S.D. Anker, A.J.S. Coats, How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int. J. Cardiol. 86, 123-130 (2002)
59. E.S. Chung, M. Packer, K.H. Lo, A.A. Fasanmade, J.T. Willerson, ATTACH Investigators, Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α in patients with moderate-to-severe heart failure. Circulation 107, 3133-3140 (2003)
60. E.P. Sampaio, E.N. Sarno, R. Galilly, G. Kaplan, Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173, 699-703 (1991)
61. L. Gullestad, A.G. Semb, E. Holt, R. Skardal, T. Ueland, A. Yndestad, S.S. Froland, P. Aukrust, Effect of thalidomide in patients with chronic heart failure. Am. Heart J. 144, 847-850 (2002)
62. L. Gullestad, J. Kiekshus, J.K. Damas, T. Ueland, A. Yndestad, P. Aukrust, Agents targeting inflammation in heart failure. Expert Opin. Investig. Drugs 14, 557-566 (2005)
63. I. Agoston, Z.I. Dibbs, F. Wang, G. Muller, J.B. Zeldis, D.L. Mann, B. Bozkurt, Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. J. Card. Fail. 8, 306-314 (2002)
64. L. Gullestad, T. Ueland, J.G. Fjeld, E. Holt, T. Gundersen, K. Breivik, M. Folling, A. Hodt, R. Skardal, J. Kjekshus, A. Andreassen, E. Kjekshus, R. Wergeland, A. Yndestad, S.S. Froland, A.G. Semb, P. Aukrust, Effect of thalidomide on cardiac remodeling in chronic heart failure. Circulation 112, 3408-3414 (2005)
65. CONSENSUS Trail Study Group, Effects of enalapril on morbidity and mortality in severe congestive heart failure. N. Engl. J. Med. 316, 1429-1431 (1987)
66. SOLVD Investigators, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293-302 (1991)
67. M.A. Pfeffer, E. Braunwald, L.A. Moye, Effects of captopril on mortality and morbidity in patients with left ventricular dysfunktion after myocardial infarction. Result of the survival and ventricular enlargement trail. N. Engl. J. Med. 327, 669-677 (1992)
68. Y.H. Song, Y. Li, J. Du, W.E. Mitch, N. Rosenthal, P. Delafontaine, Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 115, 451-458 (2005)
69. B.M. Rezk, T. Yoshida, L. Semprun-Prieto, Y. Higashi, S. Sukhanov, P. Delafontaine, Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy. PLoS ONE 7, e30276 (2012)
70. S.T. Russell, P.M. Sanders, M.J. Tisdale, Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett. 231, 290-294 (2006)
71. S.T. Russell, S.M. Wyke, M.J. Tisdale, Mechanism of induction of muscle protein degradation by angiotensin II. Cell. Signal. 18, 1087-1096 (2006)
72. T. Yoshida, L. Semprun-Prieto, S. Sukhanov, P. Delafontaine, IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am. J. Physiol. Heart Circ. Physiol. 298, H1565-H1570 (2010)
73. S.D. Anker, A. Negassa, A.J. Coats, R. Afzal, P.A. Poole-Wilson, J.N. Cohn, S. Yusuf, Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 361, 1077-1083 (2003)
74. G.D. Schellenbaum, N.L. Smith, S.R. Heckbert, T. Lumley, T.D. Rea, C.D. Furberg, M.F. Lyles, B.M. Psaty, Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension. J. Am. Geriatr. Soc. 53, 1996-2000 (2005)
75. M. Di Bari, L. Van De Poll-Franse, G. Onder, S.B. Kritchevsky, A. Newman, T.B. Harris, J.D. Williamson, N. Marchionni, M. Pahor, Antihypertensive medications and differences in muscle mass in older persons: the health, aging and body composition study. J. Am. Geriatr. Soc. 52, 961-966 (2004)
76. E.T. Poehlman, E. Danforth, Endurance training increases metabolic rate and norepinephrine appearance rate in older individuals. Am. J. Physiol. Endocrinol. Metab. 261, E233-E239 (1991)
77. S.D. Anker, T.P. Chua, P. Ponikowski, D. Harrington, J.W. Swan, W.J. Kox, P.A. Poole-Wilson, A.J.S. Coats, Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96, 526-534 (1997)
78. T.O. Obisesan, M.J. Toth, K. Donaldson, S.S. Gottlieb, M.L. Fisher, P. Vaitekevicius, E.T. Poehlman, Energy expenditure and symptom severity in men with heart failure. Am. J. Cardiol. 77, 1250-1252 (1996)
79. I.S. Anand, R. Ferrari, G.S. Kalra, P.L. Wahi, P.A. Poole-Wilson, P.C. Harris, Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 80, 299-305 (1989)
80. S.D. Anker, W. Steinborn, S. Strassburg, Cardiac cachexia. Ann. Med. 36, 518-529 (2004)
81. A.C. McPherron, A.M. Lawler, S.J. Lee, Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member. Nature 387, 83-90 (1997)
82. A.C. McPherron, S.J. Lee, Double muscling in cattle due to mutations in the myostatin gene. Proc. Natl. Acad. Sci. USA 94, 12457-12461 (1997)
83. M. Schuelke, K.R. Wagner, L.E. Stolz, C. Hubner, T. Riebel, W. Komen, T. Braun, J.F. Tobin, S.J. Lee, Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. 350, 2682-2688 (2004)
84. N.F. Gonzales-Cadavid, W.E. Taylor, K. Yaresheski, I. Sinha-Hikim, K. Ma, S. Ezzat, R. Shen, R. Lalani, S. Asa, M. Mamita, G. Nair, S. Arver, S. Bhasin, Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc. Natl. Acad. Sci. USA 95, 14938-14943 (1998)
85. K.E. Yarasheski, S. Bhasin, I. Sinha-Hikim, J. Pak-Loduca, N.F. Gonzales-Cadavid, Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting. J. Nutr. Health Aging 6, 343-348 (2002)
86. K. Lenk, R. Schur, A. Linke, S. Erbs, Y. Matsumoto, V. Adams, G. Schuler, Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur. J. Heart Fail. 11, 342-348 (2009)
87. T.A. Zimmers, M.V. Davies, L.G. Koniaris, P. Haynes, A.F. Esquela, K.N. Tomkinson, A.C. McPherron, N.M. Wolfman, S.J. Lee, Induction of cachexia in mice by systemically administered myostatin. Science 296, 1486-1488 (2002)
88. A. Rebbapragada, H. Benchabane, J.L. Wrana, A.J. Celeste, L. Attisano, Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol. Cell. Biol. 23, 7230-7242 (2003)
89. S. Tajbakhsh, D. Rocancourt, G. Cossu, M. Buckingham, Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. Cell 89, 127-138 (1997)
90. M. Maroto, R. Reshef, A.E. Münsterberg, S. Koester, M. Goulding, A.B. Lassar, Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. Cell 89, 139-148 (1997)
91. B. Langley, M. Thomas, A. Bishop, M. Sharma, S. Gilmour, R. Kambadur, Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J. Biol. Chem. 277, 49831-49840 (2002)
92. C. McFarlane, A. Hennebry, M. Thomas, E. Plummer, N. Ling, M. Sharma, R. Kambadur, Myostatin signals through Pax7 to regulate satellite cell self-renewal. Exp. Cell Res. 314, 317-329 (2008)
93. D.L. Allen, T.G. Unterman, Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am. J. Physiol. Cell Physiol. 292, C188-C199 (2007)
94. H. Amthor, G. Nicholas, I. McKinnell, C.F. Kemp, M. Sharma, R. Kambadur, K. Patel, Follistatin complexes myostatin and antagonises myostatin-mediated inhibition of myogenesis. Dev. Biol. 270, 19-30 (2004)
95. S.J. Lee, Y.S. Lee, T.A. Zimmers, A. Soleimani, M.M. Matzuk, K. Tsuchida, R.D. Cohn, E.R. Barton, Regulation of muscle mass by follistatin and activins. Mol. Endocrinol. 24, 1998-2008 (2010)
96. M.M. Matzuk, N. Lu, H. Vogel, K. Sellheyer, D.R. Roop, A. Bradley, Multiple defects and perinatal death in mice deficient in follistatin. Nature 374, 360-363 (1995)
97. S. Bogdanovich, T.O.B. Krag, E.R. Barton, L.D. Morris, L.A. Whittemore, R.S. Ahima, T.S. Khurana, Functional improvement of dystrophic muscle by myostatin blockade. Nature 420, 418-421 (2002)
98. L.A. Whittemore, K. Song, X. Li, J. Aghajanian, M. Davies, S. Girgenrath, J.J. Hill, M. Jalenak, P. Kelley, A. Knight, R. Maylor, D. O'Hara, A. Pearson, A. Quazi, S. Ryerson, X.Y. Tan, K.N. Tomkinson, G.M. Veldman, A. Widom, J.F. Wright, S. Wudyka, L. Zhao, N.M. Wolfman, Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem. Biophys. Res. Commun. 300, 965-971 (2003)
99. K.R. Wagner, J.L. Fleckenstein, A.A. Amato, R.J. Barohn, K. Bushby, D.M. Escolar, K.M. Flanigan, A. Pestronk, R. Tawil, G.I. Wolfe, M. Eagle, J.M. Florence, W.M. King, S. Pandya, V. Straub, P. Juneau, K. Meyers, C. Csimma, T. Araujo, R. Allen, S.A. Parsons, J.M. Wozney, E.R. LaVallie, J.R. Mendell, A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann. Neurol. 63, 561-571 (2008)
100. X. Zhou, J.L. Wang, J. Lu, Y. Song, K.S. Kwak, Q. Jiao, R. Rosenfeld, Q. Chen, T. Boone, W.S. Simonet, D.L. Lacey, A.L. Goldberg, H.Q. Han, Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531-543 (2010)
101. L. Zhang, V. Rajan, E. Lin, Z. Hu, H.Q. Han, X. Zhou, Y. Song, H. Min, X. Wang, J. Du, W.E. Mitch, Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. 25, 1653-1663 (2011)
102. J.M.P. Holly, C.M. Perks, C.E.H. Stewart, Overview of insulin-like growth factor physiology. Growth Horm. IGF Res. 10, S8-S9 (2000)
103. D.J. Glass, Molecular mechanisms modulating muscle mass. Trends Mol. Med. 9, 344-350 (2003)
104. N.J. Szewczyk, L.A. Jacobson, Signal-transduction networks and the regulation of muscle protein degradation. Int. J. Biochem. Cell Biol. 37, 1997-2011 (2005)
105. S. Watanabe, T. Tamura, K. Ono, H. Horiuchi, T. Kimura, T. Kita, Y. Furukawa, Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin. Eur. J. Heart Fail. 12, 1214-1222 (2010)
106. S.D. Lee, L.M. Chen, W.W. Kuo, W.T. Shu, W.H. Kuo, E.J. Huang, C.C. Tsai, P.C. Li, J.Y. Liu, T.H. Chen, C.Y. Huang, Serum insulin-like growth factor-axis and matrix metalloproteinases in patients with rheumatic arthritis or rheumatic heart disease. Clin. Chim. Acta 367, 62-68 (2006)
107. C. Rommel, S.C. Bodine, B.A. Clarke, R. Rossman, L. Nunez, T.N. Stitt, G.D. Yancopoulos, D.J. Glass, Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3, 1009-1013 (2001)
108. T. Matsui, T. Nagoshi, A. Rosenzweig, Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle 2, 20-223 (2003)
109. C. Buechler, J. Wanninger, M. Neumeier, Adiponectin receptor binding proteins - recent advances in elucidating adiponectin signalling pathways. FEBS Lett. 584, 4280-4286 (2010)
110. M. Sandri, C. Sandri, A. Gilbert, C. Skurk, E. Calabria, A. Picard, K. Walsh, S. Schiaffino, S.H. Lecker, A.L. Goldberg, FOXO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399-412 (2004)
111. M. Sandri, J. Lin, C. Handschin, W. Yang, Z.P. Arany, S.H. Lecker, A.L. Goldberg, B.M. Spiegelman, PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA 103, 16260-16265 (2006)
112. R. Bassel-Duby, E.N. Olson, Signaling pathways in skeletal muscle remodeling. Annu. Rev. Biochem. 75, 19-37 (2006)
113. C.M. Liu, Z. Yang, C.W. Liu, R. Wang, P. Tien, R. Dale, L.Q. Sun, Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther. 14, 945-952 (2007)
114. S. Genth-Zotz, R. Zotz, S. Geil, T. Voigtländer, J. Meyer, H. Darius, Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation 99, 18-21 (1999)
115. S. Fazio, D. Sabatini, B. Capaldo, C. Vigorito, A. Giordano, R. Guida, F. Pardo, B. Biondi, L. Saccá, A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N. Engl. J. Med. 334, 809-814 (1996)
116. K.J. Osterziel, O. Strohm, J. Schuler, M. Friedrich, D. Hänlein, R. Willenbrock, S.D. Anker, P. Poole-Wilson, M.B. Ranke, R. Dietz, Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 351, 1233-1237 (1998)
117. J. Isgaard, C.H. Bergh, K. Caidahl, M. Lomsky, A. Hjalmarson, B.A. Bengtsson, A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur. Heart J. 19, 1704-1711 (1998)
118. J. Takala, E. Ruokonen, N.R. Webster, M.S. Nielsen, D.F. Zandstra, G. Vundelinckx, C.J. Hinds, Increased mortality associated with growth hormone treatment in critically ill adults. N. Engl. J. Med. 341, 785-792 (1999)
119. R.C. Cuneo, P. Wilmshurst, C. Lowy, G. Mcgauley, P.H. Sönksen, Cardiac failure responding to growth hormone. Lancet 333, 838-839 (1989)
120. J.G. ODriscoll, D.J. Green, M. Ireland, D. Kerr, R.L. Larbalestier, Treatment of end-stage cardiac failure with growth hormone. Lancet 349, 1068 (1997)
121. C.J. Bagatell, W.J. Bremner, Androgens in men - uses and abuses. N. Engl. J. Med. 334, 707-715 (1996)
122. T. Montalcini, V. Migliaccio, Y. Ferro, C. Gazzaruso, A. Pujia, Androgens for postmenopausal women's health. Endocrine, (2012). doi: 10.1007/s12020-012- 9692-1
123. H.A. Feldman, C. Longcope, C.A. Derby, C.B. Johannes, A.B. Araujo, A.D. Coviello, W.J. Bremner, J.B. McKinlay, Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J. Clin. Endocrinol. Metab. 87, 589-598 (2002)
124. A.B. O′Donnell, T.G. Travison, S.S. Harris, J.L. Tenover, J.B. McKinlay, Testosterone, dehydroepiandrosterone, and physical performance in older men: results from the Massachusetts male aging study. J. Clin. Endocrinol. Metab. 91, 425-431 (2006)
125. E.A. Jankowska, B. Biel, J. Majda, A. Szklarska, M. Lopuszanska, M. Medras, S.D. Anker, W. Banasiak, P.A. Poole-Wilson, P. Ponikowski, Anabolic deficiency in men with chronic heart failure. Circulation 114, 1829-1837 (2006)
126. M. Volterrani, G. Rosano, F. Iellamo, Testosterone and heart failure. Endocrine. (2012). doi: 10.1007/s12020-012-9725-9
127. E.A. Jankowska, G. Filippatos, B. Ponikowska, L. Borodulin-Nadzieja, S.D. Anker, W. Banasiak, P.A. Poole-Wilson, P. Ponikowski, Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J. Card. Fail. 15, 442-450 (2009)
128. G. Güder, S. Frantz, J. Bauersachs, B. Allolio, G. Ertl, C.E. Angermann, S. Störk, Low circulating androgens and mortality risk in heart failure. Heart 96, 504-509 (2010)
129. E. Wehr, S. Pilz, B.O. Boehm, W. März, T. Grammer, B. Obermayer-Pietsch, Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. Eur. J. Heart Fail. 13, 482-488 (2011)
130. G. Caminiti, M. Volterrani, F. Iellamo, G. Marazzi, R. Massaro, M. Miceli, C. Mammi, M. Piepoli, M. Fini, G.M.C. Rosano, Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J. Am. Coll. Cardiol. 54, 919-927 (2009)
131. M. Toma, F.A. McAlister, E.E. Coglianese, V. Vidi, S. Vasaiwala, J.A. Bakal, P.W. Armstrong, J.A. Ezekowitz, Testosterone supplementation in heart failure/clinical perspective. Circ. Heart Fail. 5, 315-321 (2012)
132. S. Bhasin, T.W. Storer, M. Javanbakht, N. Berman, K.E. Yarasheski, J. Phillips, M. Dike, I. Sinha-Hikim, R. Shen, R.D. Hays, G. Beall, Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 283, 763-770 (2000)
133. Ss. Yeh, B. DeGuzman, T. Kramer, Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest 122, 421-428 (2002)
134. E. O′Neill, J. Wilding, C. Kahn, H. Van Remmen, A. McArdle, M. Jackson, G. Close, Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradation. AGE 32, 209-222 (2010)
135. A.A. Sayer, H.E. Syddall, E.M. Dennison, H.J. Martin, D.I.W. Phillips, C. Cooper, C.D. Byrne, Grip strength and the metabolic syndrome: findings from the Hertfordshire Cohort Study. QJM 100, 707-713 (2007)
136. S.W. Lee, G.H. Park, S.W. Lee, J.H. Song, K.C. Hong, M.J. Kim, Insulin resistance and muscle wasting in non-diabetic end-stage renal disease patients. Nephrol. Dial. Transplant. 22, 2554-2562 (2007)
137. P. Daneryd, L. Hafström, E. Svanberg, I. Karlberg, Insulin sensitivity, hormonal levels and skeletal muscle protein metabolism in tumour-bearing exercising rats. Eur. J. Cancer 31A, 97-103 (1995)
138. E. Ingelsson, J. Sundström, J. Arnlöv, B. Zethelius, L. Lind, Insulin resistance and risk of congestive heart failure. JAMA 294, 334-341 (2005)
139. Y. Ohta, S. Kinugawa, S. Matsushima, T. Ono, M.A. Sobirin, N. Inoue, T. Yokota, K. Hirabayashi, H. Tsutsui, Oxidative stress impairs insulin signal in skeletal muscle and causes insulin resistance in postinfarct heart failure. Am. J. Physiol. Heart Circ. Physiol. 300, H1637-H1644 (2011)
140. G.A. Nader, Molecular determinants of skeletal muscle mass: getting the "AKT" together. Int. J. Biochem. Cell Biol. 37, 1985-1996 (2005)
141. C. Guillet, Y. Boirie, Insulin resistance: a contributing factor to age-related muscle mass loss. Diabetes Metab. 31, 5820-5826 (2005)
142. K. Takaya, H. Ariyasu, N. Kanamoto, H. Iwakura, A. Yoshimoto, M. Harada, K. Mori, Y. Komatsu, T. Usui, A. Shimatsu, Y. Ogawa, K. Hosoda, T. Akamizu, M. Kojima, K. Kangawa, K. Nakao, Ghrelin strongly stimulates growth hormone release in humans. J. Clin. Endocrinol. Metab. 85, 4908-4911 (2000)
143. E. Arvat, M. Maccario, L. Di Vito, F. Broglio, A. Benso, C. Gottero, M. Papotti, G. Muccioli, C. Dieguez, F.F. Casanueva, R. Deghenghi, F. Camanni, E. Ghigo, Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J. Clin. Endocrinol. Metab. 86, 1169-1174 (2001)
144. D.E. Cummings, Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol. Behav. 89, 71-84 (2006)
145. C. Ledderose, S. Kreth, A. Beiras-Fernandez, Ghrelin, a novel peptide hormone in the regulation of energy balance and cardiovascular function. Recent Pat. Endocr. Metab. Immune Drug Discov. 5, 1-6 (2012)
146. N. Nagaya, J. Moriya, Y. Yasumura, M. Uematsu, F. Ono, W. Shimizu, K. Ueno, M. Kitakaze, K. Miyatake, K. Kangawa, Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110, 3674-3679 (2004)
147. Y.J. Akashi, J. Springer, S.D. Anker, Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches. Curr. Heart Fail. Rep. 2, 198-203 (2005)
148. S. Palus, R. Schur, Y.J. Akashi, B. Bockmeyer, R. Datta, H. Halem, J. Dong, M.D. Culler, V. Adams, S.D. Anker, J. Springer, Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model. PLoS One, e26865 (2011)
149. Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, J.M. Friedman, Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432 (1994)
150. S. Kamohara, R. Burcelin, J.L. Halaas, J.M. Friedman, M.J. Charron, Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389, 374-377 (1997)
151. S. Margetic, C. Gazzola, G.G. Pegg, R.A. Hill, Leptin: a review of its peripheral actions and interactions. Int. J. Obes. Relat. Metab. Disord. 26, 1407-1433 (2002)
152. R.S. Ahima, D.A. Antwi, Brain regulation of appetite and satiety. Endocrinol. Metab. Clin. North Am. 37, 811-823 (2008)
153. F. Leyva, S.D. Anker, K. Egerer, J.C. Stevenson, W.J. Kox, A.J.S. Coats, Hyperleptinaemia in chronic heart failure. Eur. Heart J. 19, 1547-1551 (1998)
154. G.S. Filippatos, K. Tsilias, K. Venetsanou, E. Karambinos, D. Manolatos, A. Kranidis, J. Antonellis, F. Kardaras, L. Anthopoulos, G. Baltopoulos, Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-alpha system. Int. J. Cardiol. 76, 117-122 (2000)
155. W. Doehner, C.D. Pflaum, M. Rauchhaus, I.F. Godsland, K. Egerer, M. Cicoira, V.G. Florea, R. Sharma, A.P. Bolger, A.J. Coats, S.D. Anker, C.J. Strasburger, Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur. J. Endocrinol. 145, 727-735 (2001)
156. P.C. Schulze, J. Kratzsch, Leptin as a new diagnostic tool in chronic heart failure. Clin. Chim. Acta 362, 1-11 (2005)
157. P.C. Schulze, J. Kratzsch, A. Linke, N. Schoene, V. Adams, S. Gielen, S. Erbs, S. Moebius-Winkler, G. Schuler, Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur. J. Heart Fail. 5, 33-40 (2003)
158. M.W. Nickola, L.E. Wold, P.B. Colligan, G.J. Wang, W.K. Samson, J. Ren, Leptin attenuates cardiac contraction in rat ventricular myocytes: role of NO. Hypertension 36, 501-505 (2000)
159. K.R. McGaffin, C.S. Moravec, C.F. McTiernan, Leptin signaling in the failing and mechanically unloaded human heart/CLINICAL PERSPECTIVE. Circ. Heart Fail. 2, 676-683 (2009)
160. M.W. Hamrick, C. Pennington, D. Newton, D. Xie, C. Isales, Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 34, 376-383 (2004)
161. S.A. Warmington, R. Tolan, S. McBennett, Functional and histological characteristics of skeletal muscle and the effects of leptin in the genetically obese (ob/ob) mouse. Int. J. Obes. Relat. Metab. Disord. 24, 1040-1050 (2000)
162. M.W. Hamrick, S. Herberg, P. Arounleut, H.Z. He, A. Shiver, R.Q. Qi, L. Zhou, C.M. Isales, Q.S. Mi, The adipokine leptin increases skeletal muscle mass and significantly alters skeletal muscle miRNA expression profile in aged mice. Biochem. Biophys. Res. Commun. 400, 379-383 (2010)
163. Y.Z. Wang, Y.N. Huang, K.Y. Sun, J.H. Qi, L. Xiang, Leptin gene transfer regulates fibromuscular development and lipid deposition in muscles via SIRT1, FOXO3a and PGC-1α in mice in vivo. Int. J. Mol. Med. 28, 617-623 (2011)
164. K. Maeda, K. Okubo, I. Shimomura, K. Mizuno, Y. Matsuzawa, K. Matsubara, Analysis of an expression profile of genes in the human adipose tissue. Gene 190, 227-235 (1997)
165. Y. Okamoto, S. Kihara, N. Ouchi, M. Nishida, Y. Arita, M. Kumada, K. Ohashi, N. Sakai, I. Shimomura, H. Kobayashi, N. Terasaka, T. Inaba, T. Funahashi, Y. Matsuzawa, Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106, 2767-2770 (2002)
166. C. Kobashi, M. Urakaze, M. Kishida, E. Kibayashi, H. Kobayashi, S. Kihara, T. Funahashi, M. Takata, R. Temaru, A. Sato, K. Yamazaki, N. Nakamura, M. Kobayashi, Adiponectin inhibits endothelial synthesis of interleukin-8. Circ. Res. 97, 1245-1252 (2005)
167. W. Koenig, N. Khuseyinova, J. Baumert, C. Meisinger, H. Löwel, Serum concentrations of adiponectin and risk of type 2 Diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-Year follow-up of a large cohort from southern Germany. J. Am. Coll. Cardiol. 48, 1369-1377 (2006)
168. J.M. Bruun, A.S. Lihn, C. Verdich, S.B. Pedersen, S. Toubro, A. Astrup, B. Richelsen, Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am. J. Physiol. Endocrinol. Metab. 285, E527-E533 (2003)
169. S.T. Gulen, F. Karadag, A.B. Karul, N. Kilicarslan, E. Ceylan, N.K. Kuman, O. Cildag, Adipokines and systemic inflammation in weight-losing lung cancer patients. Lung 190, 327-332 (2012)
170. C. Kistorp, J. Faber, S. Galatius, F. Gustafsson, J. Frystyk, A. Flyvbjerg, P. Hildebrandt, Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112, 1756-1762 (2005)
171. J. George, S. Patal, D. Wexler, Y. Sharabi, E. Peleg, Y. Kamari, E. Grossman, D. Sheps, G. Keren, A. Roth, Circulating adiponectin concentrations in patients with congestive heart failure. Heart 92, 1420-1424 (2006)
172. T. Tamura, Y. Furukawa, R. Taniguchi, Y. Sato, K. Ono, H. Horiuchi, Y. Nakagawa, T. Kita, T. Kimura, Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ. J. 71, 623-630 (2007)
173. M.B. McEntegart, B. Awede, M.C. Petrie, N. Sattar, F.G. Dunn, N.G. MacFarlane, J.J.V. McMurray, Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur. Heart J. 28, 829-835 (2007)
174. J. Fruebis, T.S. Tsao, S. Javorschi, D. Ebbets-Reed, M.R. Erickson, F.T. Yen, B.E. Bihain, H.F. Lodish, Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. USA 98, 2005-2010 (2001)
175. Y. Qi, N. Takahashi, S.M. Hileman, H.R. Patel, A.H. Berg, U.B. Pajvani, P.E. Scherer, R.S. Ahima, Adiponectin acts in the brain to decease body weight. Nat. Med. 10, 524-529 (2004)
176. An.M. Van Berendoncks, P. Beckers, V.Y. Hoymans, N. Possemiers, F.L. Wuyts, C.J. Vrints, V.M. Conraads, Exercise training reduces circulating adiponectin levels in patients with chronic heart failure. Clin. Sci. 118, 281-289 (2010)
177. S. Adamopoulos, J. Parissis, C. Kroupis, M. Georgiadis, D. Karatzas, G. Karavolias, K. Koniavitou, A.J.S. Coats, D.Th. Kremastinos, Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. Eur. Heart J. 22, 791-797 (2001)
178. N.A. Smart, A.I. Larsen, J.P. Le Maitre, A.S. Ferraz, Effect of exercise training on interleukin-6, tumour necrosis factor alpha and functional capacity in heart failure. Cardiol. Res. Pract. 2011, 532620 (2011)
179. S. Gielen, V. Adams, S. Möbius-Winkler, A. Linke, S. Erbs, J. Yu, W. Kempf, A. Schubert, G. Schuler, R. Hambrecht, Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J. Am. Coll. Cardiol. 42, 861-868 (2003)
180. J. Batista, J.C. Rosa, R.D. Lopes, F.S. Lira, J. Martins, A.S. Yamashita, P.C. Brum, J. Lancha, A.C. Lopes, M. Seelaender, Exercise training changes IL-10/TNF-[alpha] ratio in the skeletal muscle of post-MI rats. Cytokine 49, 102-108 (2010)
181. A. Linke, V. Adams, P.C. Schulze, S. Erbs, S. Gielen, E. Fiehn, S. Möbius-Winkler, A. Schubert, G. Schuler, R. Hambrecht, Antioxidative effects of exercise training in patients with chronic heart failure. Increase in radical scavenger enzyme activity in skeletal muscle. Circulation 111, 1763-1770 (2005)
182. S. Gielen, M. Sandri, I. Kozarez, J. Kratsch, D. Teupser, J. Thiery, S. Erbs, N. Mangner, K. Lenk, R. Hambrecht, G. Schuler, V. Adams, Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized leipzig exercise intervention in chronic heart failure and aging (LEICA) catabolism study. Circulation 125, 2716-2727 (2012)
183. R. Höllriegel, E.B. Beck, A. Linke, V. Adams, S. Möbius-Winkler, N. Mangner, M. Sandri, S. Gielen, M. Gutberlet, R. Hambrecht, G. Schuler, S. Erbs, Anabolic effects of exercise training in patients with advanced chronic heart failure (NYHA IIIb): impact on ubiquitin-protein ligases expression and skeletal muscle size. Int. J. Cardiol., (2012)
184. S. Fujita, T. Abe, M.J. Drummond, J.G. Cadenas, H.C. Dreyer, Y. Sato, E. Volpi, B.B. Rasmussen, Blood flow restriction during low-intensity resistance exercise increases S6K1 phosphorylation and muscle protein synthesis. J. Appl. Physiol. 103, 903-910 (2007)
185. K. Baar, K. Esser, Phosphorylation of p70S6k correlates with increased skeletal muscle mass following resistance exercise. Am. J. Physiol. Cell Physiol. 276, C120-C127 (1999)
186. R. Hambrecht, P.C. Schulze, S. Gielen, A. Linke, S. Möbius-Winkler, S. Erbs, J. Kratzsch, A. Schubert, V. Adams, G. Schuler, Effects of exercise training on insulin-like growth factor-I expression in the skeletal muscle of non-cachectic patients with chronic heart failure. Eur. J. Cardiovasc. Prev. Rehabil. 12, 401-416 (2005)